Cargando…

SARS-CoV-2 vaccine development

SARS-CoV-2 is a well-known viral strain that causes COVID-19. The disease became a pandemic in early 2020 and infected millions of people and killed hundreds of thousands of people worldwide. Vaccine development against the disease was accelerated with multiple collaborations among research institut...

Descripción completa

Detalles Bibliográficos
Autores principales: Mtewa, Andrew G., Amanjot, Annu, Lampiao, Fanuel, Okella, Hedmon, Weisheit, Anke, Tolo, Casim U., Ogwang, Patrick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9217717/
http://dx.doi.org/10.1016/B978-0-323-85156-5.00046-8
_version_ 1784731714053996544
author Mtewa, Andrew G.
Amanjot, Annu
Lampiao, Fanuel
Okella, Hedmon
Weisheit, Anke
Tolo, Casim U.
Ogwang, Patrick
author_facet Mtewa, Andrew G.
Amanjot, Annu
Lampiao, Fanuel
Okella, Hedmon
Weisheit, Anke
Tolo, Casim U.
Ogwang, Patrick
author_sort Mtewa, Andrew G.
collection PubMed
description SARS-CoV-2 is a well-known viral strain that causes COVID-19. The disease became a pandemic in early 2020 and infected millions of people and killed hundreds of thousands of people worldwide. Vaccine development against the disease was accelerated with multiple collaborations among research institutions in order to shorten the duration that vaccine development normally takes. Prior coronavirus vaccines present a basis on which vaccines against the current strain can be developed with much speed and relative ease. Among the patented coronavirus vaccines, DNA-based vaccine had the most patents registered which must have clues to guide the efforts in the current works. This work presents some progress on COVID-19 vaccine development and also possible animal venom protein sources that can potentially be used in the pipeline. The future of COVID-19 vaccine is bright with the heightened collaborative efforts and data sharing opportunities that the pandemic has brought among researchers.
format Online
Article
Text
id pubmed-9217717
institution National Center for Biotechnology Information
language English
publishDate 2022
record_format MEDLINE/PubMed
spelling pubmed-92177172022-06-23 SARS-CoV-2 vaccine development Mtewa, Andrew G. Amanjot, Annu Lampiao, Fanuel Okella, Hedmon Weisheit, Anke Tolo, Casim U. Ogwang, Patrick Coronavirus Drug Discovery Article SARS-CoV-2 is a well-known viral strain that causes COVID-19. The disease became a pandemic in early 2020 and infected millions of people and killed hundreds of thousands of people worldwide. Vaccine development against the disease was accelerated with multiple collaborations among research institutions in order to shorten the duration that vaccine development normally takes. Prior coronavirus vaccines present a basis on which vaccines against the current strain can be developed with much speed and relative ease. Among the patented coronavirus vaccines, DNA-based vaccine had the most patents registered which must have clues to guide the efforts in the current works. This work presents some progress on COVID-19 vaccine development and also possible animal venom protein sources that can potentially be used in the pipeline. The future of COVID-19 vaccine is bright with the heightened collaborative efforts and data sharing opportunities that the pandemic has brought among researchers. 2022 2022-06-10 /pmc/articles/PMC9217717/ http://dx.doi.org/10.1016/B978-0-323-85156-5.00046-8 Text en Copyright © 2022 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Mtewa, Andrew G.
Amanjot, Annu
Lampiao, Fanuel
Okella, Hedmon
Weisheit, Anke
Tolo, Casim U.
Ogwang, Patrick
SARS-CoV-2 vaccine development
title SARS-CoV-2 vaccine development
title_full SARS-CoV-2 vaccine development
title_fullStr SARS-CoV-2 vaccine development
title_full_unstemmed SARS-CoV-2 vaccine development
title_short SARS-CoV-2 vaccine development
title_sort sars-cov-2 vaccine development
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9217717/
http://dx.doi.org/10.1016/B978-0-323-85156-5.00046-8
work_keys_str_mv AT mtewaandrewg sarscov2vaccinedevelopment
AT amanjotannu sarscov2vaccinedevelopment
AT lampiaofanuel sarscov2vaccinedevelopment
AT okellahedmon sarscov2vaccinedevelopment
AT weisheitanke sarscov2vaccinedevelopment
AT tolocasimu sarscov2vaccinedevelopment
AT ogwangpatrick sarscov2vaccinedevelopment